Porto

• Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended recruitment
  2023-505699-31-00 5 2017-01-02 Ulcerative Colitis
• PhII Trial of Pembrolizumab in Advanced Solid Tumors Ended recruitment
  2022-501253-37-00 4 2016-02-02 (A) Anal Squamous Cell Carcinoma, (B) Biliary Adenocarcinoma (gallblad
• Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun … Ended recruitment
  2023-505981-26-00 5 2015-11-20 Non−Small Cell Lung Cancer
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• An open-label extension study of pertuzumab administered on its own or in combination with other anti-cancer therapies in patients previousl … Ended recruitment
  2023-505102-42-00 5 2014-12-18 Solid Malignant Tumors
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Ended recruitment
  2023-503803-27-00 5 2013-10-25 B-cell non-Hodgkin's lymphoma and cGVHD
• A Phase 3 Study of NTLA 2001 in participants with amyloidosis with cardiac muscle disease. Halted
  2023-507220-23-00 5 2024-07-26 Transthyretin Amyloidosis with Cardiomyopathy
• Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta … Halted
  2024-511708-18-00 4 2022-12-06 Locally advanced or metastatic KRAS G12C-mutated non-small cell lung c
• Safety and tolerability of medicated chewing gum with sodium alginate, calcium carbonate and sodium bicarbonate. Ended
  2025-524102-15-00 3 2026-04-29 No medical condition.
• Bioequivalence of Testosterone Transdermal Gel in Healthy Female Participants. Ended
  2025-523300-77-00 2 2026-01-26 No medical conditions.
• Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions. Ended
  2025-522626-12-00 2 2025-12-18 No medical condition.
• Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin. Ended
  2024-519851-27-00 2 2025-12-09 No medical condition.
• Bioequivalence of Cinnarizine/Dimenhydrinate 20 mg/40 mg Tablets in Healthy Participants Under Fed Conditions. Ended
  2025-523948-12-00 2 2025-11-27 No medical condition.
• Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin. Ended
  2024-519849-29-00 2 2025-10-27 No medical condition.
• Multiple-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Participants. Ended
  2025-523419-12-00 3 2025-10-15 No medical condition.
• Bioequivalence of Lenvatinib 10 mg Capsules in Healthy Participants Under Fasting Conditions Ended
  2025-522259-24-00 2 2025-10-06 No medical condition
• Evaluating Bioequivalence of a Fixed Dose Combination versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin. Ended
  2024-519852-10-00 2 2025-09-10 No medical condition.
• Evaluation of the Effect of Food, Itraconazole, and Rifampicin on the Single-Dose Pharmacokinetics of Naronapride. Ended
  2024-520215-40-00 3 2025-09-09 No medical condition.
• Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin. Ended
  2024-519850-35-00 2 2025-09-04 No medical condition
• A study to test a single administration of three dose levels of ATX101 in healthy adults. Ended
  2025-521999-56-00 3 2025-07-16 Treatment of vascular hyperpermeability in patients with sepsis and se
• Bioequivalence of Canagliflozin 300 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions. Ended
  2024-519109-36-00 2 2025-07-09 No medical condition.
• Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants. Ended
  2025-520737-23-00 2 2025-07-07 No medical condition.

Showing 385–408 of 548 trials